Int. J. Dev. Biol. 54: 699 - 705 (2010)
doi: 10.1387/ijdb.092953hk
© UBC Press

Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice

Hiromitsu Kajiyama1, Tatsuo S. Hamazaki2, Makoto Tokuhara2, Shinji Masui2, Koji Okabayashi1, Kiyoshi Ohnuma1, Shigeharu Yabe2, Kazuki Yasuda3, Shoichi Ishiura1, Hitoshi Okochi2 and Makoto Asashima*,1,4

1Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 2Department of Tissue Regeneration, Research Institute, International Medical Center of Japan, Toyama, Tokyo, 3Department of Metabolic Disorder, Research Institute, International Medical Center of Japan, Tokyo and 4Organ Development Research Laboratory, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

ABSTRACT Insulin-dependent diabetes mellitus (IDDM) is characterized by the rapid development of potentially severe metabolic abnormalities resulting from insulin deficiency. The transplantation of insulin-producing cells is a promising approach for the treatment of IDDM. The transcription factor pancreatic duodenal homeobox 1 (Pdx1) plays an important role in the differentiation of pancreatic beta cells. In this study, the human Pdx1 gene was transduced and expressed in murine adipose tissue-derived stem cells (ASCs). To evaluate pancreatic repair, we used a mouse model of pancreatic damage resulting in hyperglycemia, which involves injection of mice with streptozotocin (STZ). STZ-treated mice transplanted with Pdx1-transduced ASCs (Pdx1-ASCs) showed significantly decreased blood glucose levels and increased survival, when compared with control mice. While stable expression of Pdx1 in ASCs did not induce the pancreatic phenotype in vitro in our experiment, the transplanted stem cells became engrafted in the pancreas, wherein they expressed insulin and C-peptide, which is a marker of insulin-producing cells. These results suggest that Pdx1-ASCs are stably engrafted in the pancreas, acquire a functional beta-cell phenotype, and partially restore pancreatic function in vivo. The ease and safety associated with extirpating high numbers of cells from adipose tissues support the applicability of this system to developing a new cell therapy for IDDM.

Keywords:

ASC, in vivo differentiation, Pdx1, stem cell therapy, type 1 diabetes

*Corresponding author e-mail: asashi@bio.c.u-tokyo.ac.jp